ISID-PFIZER 2021 GRANT CHALLENGE


Name: 
The International Society for Infectious Diseases (ISID) & Pfizer Announce A Quality Improvement Grant Request For Proposal (RFP) ISID-Pfizer 2021 Grant Challenge Competitive Grant Program 

Background
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in practice as outlined in the specific RFP. For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. 

Eligibility Geographic Scope
Low-income countries designated by the World Bank

AND/OR

Under resourced settings in middle-income countries as designated by the World Bank where limited capital and human resources create barriers to meeting outpatient antimicrobial prescribing needs of the population being served.

Lists of low-income and middle-income countries designated by the World Bank can be accessed at World Bank Country and Lending

Applicant Eligibility Criteria
Only organizations are eligible to receive grants, not individuals or medical practice groups.

The following may apply in this grant challenge: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations; government agencies; and other entities with a mission related to healthcare improvement. 

Collaborations within or between institutions (e.g., between departments and/or inter-professional) are encouraged. Please note, all partners must have a relevant role and the requesting organization must have a key role in the project.

For programs offering education credit, the requesting organization must be the accredited grantee.

Any grant requestor seeking funding through this grant challenge must be an existing antimicrobial stewardship program or center. No funding will be provided to establish a new center or hospital-based antimicrobial stewardship initiative.

All organizations applying for this grant challenge must be located in the geographic scope of eligibility in a low or middle-income country (LMIC). If the applying organization is not located in an LMIC, the program will be disqualified.

Date RFP Issued: 17 May 2021

Clinical Area
Anti-Infective: Antimicrobial Stewardship (AMS) in the Outpatient Setting

Scientific Area of Interest for the RFP
Proposals should focus on antimicrobial therapy consumption, use patterns, and stewardship efforts in the outpatient setting, in low-income countries or under-resourced settings in middle-income countries. Antimicrobial stewardship programs confined to the clinical healthcare setting are not enough to effectively prevent the development and spread of antimicrobial resistance. Patient use behaviors, spurred by access to antimicrobial therapies in settings outside of traditional hospitals, are a neglected area that will benefit from novel antimicrobial stewardship programs. 

For the purpose of this grant challenge, outpatient setting is defined as any setting providing antimicrobial dispensation to patients who are not admitted to a hospital especially, but not only, in low-resource settings and in countries with a high proportion of unprescribed antibiotic sales where pharmacies and other private drug stores represent the primary access points for antimicrobials.

Target Audience
Grant requestors should carefully consider the populations visiting outpatient facilities responsible for antimicrobial therapy dispensing to the general public and which population(s) will likely derive the greatest benefit from an antimicrobial stewardship program. 

Recommendations and Target Metrics
All programs should focus on outpatient healthcare settings with the goal of improving appropriate antimicrobial therapy use behaviors. Metrics should be selected based on the proposed target community and must consider health outcomes for this population. 

Expected Approximate Monetary Range of Grant Applications
Proposals from eligible organizations requesting up to $100,000 will be considered. The total available budget related to this RFP is $1,000,000.

The amount of the grant Pfizer will be prepared to fund will depend upon the external review panel’s evaluation of the proposal and costs involved and will be stated clearly in the approval notification.

Key Dates
RFP release date: 17 May 2021

LOI due date: 18 June 2021
Please note the deadline is 23:59 Eastern Time (New York, GMT -5)

Review of LOIs by External Review Panel: July 2021

Anticipated LOI Notification Date: 26 July 2021

Full Proposal Deadline: 23 August 2021
Only accepted LOIs will be invited to submit full proposals Please note the deadline is 23:59 Eastern Time (New York, GMT -5)

Review of Full Proposals by External Review Panel: September 2021

Anticipated Full Proposal Notification Date: October 2021
Grants distributed following execution of fully signed Letter of Agreement Anticipated 

Project Start and End Dates: January 1, 2022 to December 31, 2024

How to Submit
Please go to www.cybergrants.com/pfizer/loi and sign in. First-time users should click “REGISTER NOW”.

Select the following Competitive Grant Program Name: [2021 G – ISID-Pfizer 2021 Grant Challenge].

Requirements for submission
Complete all required sections of the online application and upload the completed LOI template.

If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page. 

IMPORTANT: Be advised that applications submitted through the wrong application type and/or submitted after the due date will not be considered.

Questions
If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Ai Ping Lee (AiPing.Lee@pfizer.com) with the subject line “ISID-Pfizer 2021 Grant Challenge – May 2021."

Addition information can be found here.

Comments

Popular posts from this blog

DON’T BE A DATA POINT ON THE COVID DEATH CHART

THE PATRON OF PREBENDALISM EYES ASO ROCK (PART II)

MY DAD AND HIS GIFTS OF COLLEGE T-SHIRT SOUVENIRS